Unlocking the EGFR-mediated epitranscriptome: A pathway to novel therapies
- PMID: 38065059
- DOI: 10.1016/j.molcel.2023.10.044
Unlocking the EGFR-mediated epitranscriptome: A pathway to novel therapies
Abstract
In this issue, Lv et al.1 explore EGFR-driven epitranscriptomic reprogramming in glioblastoma, revealing the pivotal role of the EGFR-ALKBH5-GCLM axis in ferroptosis protection. Their findings offer mechanistic insight and therapeutic strategies involving novel combination targets to enhance tumor responses.
Copyright © 2023 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests The authors declare no conflicts of interest.
Comment on
-
EGFR promotes ALKBH5 nuclear retention to attenuate N6-methyladenosine and protect against ferroptosis in glioblastoma.Mol Cell. 2023 Dec 7;83(23):4334-4351.e7. doi: 10.1016/j.molcel.2023.10.025. Epub 2023 Nov 17. Mol Cell. 2023. PMID: 37979586 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials